期刊文献+

追毒方逆转三阴性乳腺癌MDA-MB-231细胞耐药的作用机制 被引量:3

Reverse Effect and Mechanism of Effective Components of Zhuidu Fang on Triple Negative Breast Cancer MDA-MB-231 Drug-Resistant Cells
下载PDF
导出
摘要 目的基于糖基转移酶β3GnT8探讨追毒方逆转三阴性乳腺癌MDA-MB-231细胞耐药的作用机制。方法通过MTT法观察追毒方对MDA-MB-231耐药细胞增殖的抑制作用,通过转染β3GnT8得到高表达β3GnT8的MDA-MB-231/TAX细胞株,采用Western blot观察糖基转移酶β3GnT8和耐药蛋白BCRP、P-gp的表达,通过凝集素流式细胞术观察转染β3GnT8MDA-MB-231/TAX细胞膜表面β3GnT8的荧光强度。结果追毒方有效成分能明显抑制三阴性乳腺癌MDA-MB-231耐药细胞的增殖,作用72h抑制率达到50.16%,能有效下调β3GnT8和耐药蛋白BCRP、P-gp的表达,并且β3GnT8的表达与BCRP、P-gp呈正相关。结论追毒方可通过下调糖基转移酶β3GnT8,从而降低耐药蛋白BCRP、P-gp的表达,逆转三阴性乳腺癌MDA-MB-231细胞耐药性。 OBJECTIVE Based on glycosyltransferaseβ3 GnT8,to investigate the mechanism of reverse effect on triple negative breast cancer MDA-MB-231 drug-resistance cells by Zhuidu Fang.METHODS The inhibition of MDA-MB-31 drug-resistance cells proliferation by Zhuidu Fang was detected by MTT assay.By interference and transfection ofβ3 GnT8,high and low expressedβ3 GnT8 MDA-MB-231/TAX cell lines were obtained.Western blot was used to detect the protein expression ofβ3 GnT8,and drug resistance protein BCRP and P-gp.Lectin flow cytometry was used to detectβ3 GnT8 fluorescence intensity onβ3 GnT8 transfected MDA-MB-231/TAX cells.RESULTS Zhuidu Fang effectively inhibited the proliferation of MDA-MB-231/TAX cells,and the inhibitory rate was 50.16%after 72 h.Zhuidu Fang significantly downregulated the protein expression ofβ3 GnT8,BCRP and P-gp.The protein expression ofβ3 GnT8 showed a positive correlation with BCRP and P-gp.CONCLUSION Zhuidu Fang can reverse the drug-resistance of MDA-MB-231 cell lines,which is associated with the downregulation of the expression ofβ3 GnT8,BCRP and P-gp.
作者 刘敏 刘春亮 梁国强 姚霏 张晓迪 陈婷 袁雅琴 吴士良 LIU Min;LIU Chun liang;LIANG Guo qiang;YAO Fei;ZHANG Xiao die;CHEN Ting;YUAN Ya qin;WU Shi liang(Affiliated Suzhou Hospital of TCM to Nanjing University of Chinese Medicine,Suzhou,215009,China;School of Biology and Basic Medical Sciences,Soochow University,Suzhou,215123,China)
出处 《南京中医药大学学报》 CAS CSCD 北大核心 2019年第1期63-67,共5页 Journal of Nanjing University of Traditional Chinese Medicine
基金 江苏省苏州市科技局项目(SYS201572)
关键词 追毒方 三阴性乳腺癌MDAMB231耐药细胞 β3GnT8 逆转耐药 Zhuidu Fang triple negative breast cancer MDA-MB-231 drug resistance cells β3GnT8 reverse the drug-resistance
  • 相关文献

参考文献2

二级参考文献38

  • 1Dickler MN, Barry WT, Cirrincione CT, et al. Phase m trial e- valuating the addition of bevacizumab to letrozole as first-line endo- crine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance) [ C ]. J Clin Oncol, 2015, 33 ( suppl aS01 ).
  • 2Gralow J, Barlow WE, Paterson AHG, et al. Phase R[ trial of bi- sphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307 [ C ]. J Clin Oncol, 2015, 33 (suppl a503).
  • 3Gnant M, Pfeiler G, Duhsky PC, et al. Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial[ C ]. J Clin Oncol, 2015, 33 ( suppl a504).
  • 4Gianni L, Pienkowski T, Im YH, et al. Five-year analysis of the phase ]I NeoSphere trial evaluating four cycles of neoadjuvant do- cetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P) [ C ]. J Clin Oncol, 2015, 33 (suppl a505).
  • 5Harbeck N, Ghz O, Christgen M, et al. Efficacy of 12-weeks of neoadjuvant TDM1 with or without endocrine therapy in HER2- positive hormone-receptor-positive early breast cancer: WSG-A- DAPT HER2 +/HR + phase II trial[C]. J Clin Oncol, 2015, 33 ( suppl a506 ).
  • 6Ellis PA, Barrios CH, Eiermann W,et al. Phase 111, randomized study of trastuzumab emtansine (T-DM1) + pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of I-IER2-posi- tive MBC: Primary results from the MARIANNE study[ C]. J Clin Oncol, 2015, 33(suppl a507).
  • 7Chan A, Delaloge S, Holmes FA, et al. Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast canc- er: Primary analysis at 2 years of a phase 3, randomized, placebo- controlled trial (ExteNET) [ C ]. J Clin Oncol, 2015, 33 ( suppl a508).
  • 8Stover DG, Selfors LM, Coloff JL, et al. Meta-analysis of breast cancer expression data using published gcne signatures to reveal key cellular processes implicated in chemosensitivity and resistance [ C]. J Clin Oncol, 2015, 33( suppl a509).
  • 9Vinayak S, Gray P,J, Adams S, et al. Association of increased tumor-infiltrating lymphocytes ( TILs ) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to nenadjuvant platinum-based therapy in PrECOGO105 [ C ]. J Clin Oncol, 2014,32:5 s ( suppl alO00 ).
  • 10Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8 ~ and FOXP3 ~ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer[ C ]. J Clin Oncol, 2015, 33 ( suppl a510).

共引文献25

同被引文献38

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部